MolecularMD Licenses Rights to Commercialize Technology Aimed at Endometrial Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD said today it has secured the rights to commercialize IP surrounding fibroblast growth factor receptor 2 activating mutations for diagnostic, prognostic, and predictive purposes in human endometrial cancer.

Rights to the IP are jointly held by Washington University in St. Louis and the Translational Genomics Research Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."